- Home
- GUTS vs CNTB Comparison
GUTS vs CNTB Comparison
Compare GUTS & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GUTS
- CNTB
- Stock Information
- Founded
- GUTS 2010
- CNTB 2012
- Country
- GUTS United States
- CNTB United States
- Employees
- GUTS N/A
- CNTB N/A
- Industry
- GUTS
- CNTB Biotechnology: Pharmaceutical Preparations
- Sector
- GUTS
- CNTB Health Care
- Exchange
- GUTS NYSE
- CNTB Nasdaq
- Market Cap
- GUTS 58.8M
- CNTB 54.4M
- IPO Year
- GUTS 2024
- CNTB 2021
- Fundamental
- Price
- GUTS $1.92
- CNTB $2.22
- Analyst Decision
- GUTS Buy
- CNTB Strong Buy
- Analyst Count
- GUTS 1
- CNTB 2
- Target Price
- GUTS $10.00
- CNTB $7.50
- AVG Volume (30 Days)
- GUTS 450.6K
- CNTB 251.3K
- Earning Date
- GUTS 08-13-2025
- CNTB 09-04-2025
- Dividend Yield
- GUTS N/A
- CNTB N/A
- EPS Growth
- GUTS N/A
- CNTB N/A
- EPS
- GUTS N/A
- CNTB N/A
- Revenue
- GUTS $60,000.00
- CNTB $26,033,000.00
- Revenue This Year
- GUTS N/A
- CNTB N/A
- Revenue Next Year
- GUTS N/A
- CNTB N/A
- P/E Ratio
- GUTS N/A
- CNTB N/A
- Revenue Growth
- GUTS N/A
- CNTB N/A
- 52 Week Low
- GUTS $0.87
- CNTB $0.51
- 52 Week High
- GUTS $4.37
- CNTB $2.86
- Technical
- Relative Strength Index (RSI)
- GUTS 58.78
- CNTB 72.32
- Support Level
- GUTS $1.84
- CNTB $1.79
- Resistance Level
- GUTS $1.95
- CNTB $2.86
- Average True Range (ATR)
- GUTS 0.11
- CNTB 0.31
- MACD
- GUTS 0.05
- CNTB 0.09
- Stochastic Oscillator
- GUTS 90.00
- CNTB 64.64
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.